Mike Hollan

Pharma companies have the choice of facing strict tariffs or negotiating with the current administration.

Gen Li, founder and president of Phesi, discusses how the industry is considering GLP-1s from a more holistic approach.

Products tested and manufactured exclusively from domestic materials will be eligible for the program.

Kitamura discusses implementing cost management initiatives and positioning the company to weather near-term challenges.

Gen Li, founder and president of Phesi, discusses how the rise of GLP-1 medications is impacting how various diseases are treated beyond the ones the medications are specifically designed to treat.

This marks the latest change in the President’s strategy.

Details of the agreement are confidential, but it reportedly fulfills the requirements President Trump set forth in a July 31st letter to the company.

The MFN executive order may result in the US losing its place as the friendliest market for innovation.

The move will allow stocks to be traded across the US, London, and Stockholm exchanges.

The news comes just days after President Trump’s announcement on 100%-pharma tariffs.

The founder of InflaRX discusses lessons learned during the COVID-19 pandemic and how they’re being applied in a post-pandemic world.

While the MFN executive order targets drug companies for drug prices, Peter Rubin discusses how health plans also play a large role in this area.

Companies that have broken ground or begun construction on US manufacturing sites will be exempt from these tariffs.

Ryan Quigley, CEO of Inizio, explains the impact of advancements and innovations and how they’re making pharma more personalized.

Peter Rubin discusses how effective President Trump’s executive order could actually be against the factors that dictate drug pricing.

Kalundborg is home to a major Novo Nordisk factory which is likely to impacted by layoffs.

The company did not provide a reason for the bimagrum trial’s halting.

Aside from pricing changes, the impacts that MFN could have on the US market could have global reverberations.

Following the President’s claims connecting the drug to an increased risk of autism when used during pregnancy, Tylenol has found itself in an unexpected spotlight.

Ryan Quigley, CEO of Inizio, details the current usage of AI and other advanced technologies.

In order to enforce MFN, regulatory agencies must navigate the complex process of determining a drug’s true value.

Investor reaction is showing how the industry is reacting to the President’s claims.

The President announced FDA will no longer recommend the use of the common painkiller during pregnancy, despite a casual link between the medication and autism not being established.

Pacira BioSciences’ CEO discusses research into pain treatment that has less chance of creating dependency and addiction issues.

Alongside regulations from the IRA, oncology R&D is set to face unique challenges when MFN is enforced.

Peter Rubin discusses how the industry is an ecosystem and each of the parts will feel the impact differently.

Ryan Quigley, CEO of Inizio, explains how AI, personalized medicine, and GLP 1s are shaping commercialization trends.

Ryan Quigley, CEO of Inizio, discusses how advancement in science are changing the pace of commercialization.

The HOSP Alliance leader discusses the role of specialty pharmacies in the current market.

The company announced the plans as President visited the UK.